Trial
NCT00625729
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
National Cancer Institute (NCI)
Condition
Leukemia
Intervention
aldesleukin
Why stopped
No patients exhibited natural killer cell expansion (primary endpoint).
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-28